A multicentre, double-blind, randomised, placebo – controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in the course of Major Depressive Disorder

This multicentre, double-blind, randomised, placebo-controlled Phase II trial (n=88) assessed the efficacy, safety, and pharmacokinetics of inhaled esketamine in subjects with treatment-resistant depression (TRD) in the course of major depressive disorder.

Conducted by Celon Pharma SA in Poland, the trial aimed to determine Esketamine’s effectiveness, dose-response, and safety compared to a placebo. The primary outcome was measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 14. Secondary objectives included evaluating the effect, durability, safety, and pharmacokinetic properties of Esketamine.

Exploratory objectives focused on genetic and biomarker correlations. The trial, part of a paediatric investigation plan, was authorised by the competent authority on August 29, 2018, and completed on April 24, 2020. The trial involved adult subjects, both male and female and had multiple sites across Poland.

Topic Treatment-Resistant Depression Depression
Compound Ketamine Placebo
Country Poland
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.